Flow Traders U.S.’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Flow Traders U.S.’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-17,881	Closed	-$262K	–	869
2022 Q3	$262K	Buy	+17,881	New	+$288K	0.01%	669
2022 Q1	–	Sell	-9,923	Closed	-$236K	–	807
2021 Q4	$236K	Sell	9,923 -839	-8%	-$23.3K	0.01%	677
2021 Q3	$327K	Sell	10,762 -24,997	-70%	-$755K	0.01%	810
2021 Q2	$1.14M	Buy	+35,759	New	+$1.08M	0.06%	373

Other funds holding CNCR

BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Flow Traders U.S.'s CNCR Position: Q4 2022 in Review

Flow Traders U.S. sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q4 2022, closing a stake of 17,881 shares — an estimated $262K sold.

Flow Traders U.S. first reported a position in CNCR in Q2 2021 and held it in 4 quarters. The position peaked at $1.14M in Q2 2021. 20 funds tracked by Wall St. Rank hold CNCR as of Q4 2022.

Flow Traders U.S. reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q4 2022 after selling out during the quarter.
Flow Traders U.S. sold 17,881 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q4 2022, an estimated $262K.
Flow Traders U.S. first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q2 2021 and held it in 4 quarters.
Flow Traders U.S.'s ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $1.14M in Q2 2021.
20 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q4 2022.

Based on Flow Traders U.S.'s 13F filing for Q4 2022, filed 14 Feb 2023.